109 related articles for article (PubMed ID: 30905538)
1. Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population.
Morales-Chacón K; Bourlon C; Acosta-Medina AA; Bourlon MT; Aguayo A; Tuna-Aguilar E
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e299-e306. PubMed ID: 30905538
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of clinical features and prognosis of patients with chronic myelogenous leukemia harboring additional chromosomal abnormalities in Ph-positive cells].
Dong XY; Li YL; Wu CY; Shang BJ; Zhang L; Cheng W; Zhu ZM
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):660-665. PubMed ID: 34547872
[No Abstract] [Full Text] [Related]
3. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
Millot F; Dupraz C; Guilhot J; Suttorp M; Brizard F; Leblanc T; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A; Guilhot F
Cancer; 2017 Sep; 123(18):3609-3616. PubMed ID: 28497898
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
[TBL] [Abstract][Full Text] [Related]
5. The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study.
Savasoglu K; Payzin KB; Ozdemirkiran F; Subasioglu A; Yilmaz AF
Leuk Lymphoma; 2017 Aug; 58(8):1958-1962. PubMed ID: 27924671
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of cytogenetic monitoring in chronic myeloid leukemia].
Pan CY; Xu N; He BL; Cao R; Liao LB; Yin CX; Lan YQ; Lu ZY; Huang JX; Sun J; Feng R; Liu QF; Liu XL
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):112-117. PubMed ID: 28279034
[No Abstract] [Full Text] [Related]
7. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
Alhuraiji A; Kantarjian H; Boddu P; Ravandi F; Borthakur G; DiNardo C; Daver N; Kadia T; Pemmaraju N; Pierce S; Garcia-Manero G; Wierda W; Verstovsek S; Jabbour E; Cortes J
Am J Hematol; 2018 Jan; 93(1):84-90. PubMed ID: 29027261
[TBL] [Abstract][Full Text] [Related]
8. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Fabarius A; Leitner A; Hochhaus A; Müller MC; Hanfstein B; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Reiter A; Jung-Munkwitz S; Proetel U; Schwaab J; Hofmann WK; Schubert J; Einsele H; Ho AD; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Lauseker M; Pfirrmann M; Hasford J; Saussele S; Hehlmann R;
Blood; 2011 Dec; 118(26):6760-8. PubMed ID: 22039253
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Wang W; Cortes JE; Tang G; Khoury JD; Wang S; Bueso-Ramos CE; DiGiuseppe JA; Chen Z; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2016 Jun; 127(22):2742-50. PubMed ID: 27006386
[TBL] [Abstract][Full Text] [Related]
10. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
[TBL] [Abstract][Full Text] [Related]
11. [The influence of additive clonal chromosome abnormalities in Ph negative cells on the efficacy of chronic myeloid leukemia].
Zhao HF; Zhang Y; Zu YL; Li Z; Zhou J; Yu FK; Hu JY; Wei XD; Song YP
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):803-807. PubMed ID: 31665854
[No Abstract] [Full Text] [Related]
12. BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Pagnano KB; Bendit I; Boquimpani C; De Souza CA; Miranda EC; Zalcberg I; Larripa I; Nardinelli L; Silveira RA; Fogliatto L; Spector N; Funke V; Pasquini R; Hungria V; Chiattone CS; Clementino N; Conchon M; Moiraghi EB; Lopez JL; Pavlovsky C; Pavlovsky MA; Cervera EE; Meillon LA; Simões B; Hamerschlak N; Bozzano AH; Mayta E; Cortes J; Bengió RM;
Cancer Invest; 2015; 33(9):451-8. PubMed ID: 26288116
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches.
Asnafi AA; Deris Zayeri Z; Shahrabi S; Zibara K; Vosughi T
J Cell Physiol; 2019 May; 234(5):5798-5806. PubMed ID: 30430567
[TBL] [Abstract][Full Text] [Related]
14. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
15. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
16. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
17. High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R; Voskanyan A; Lauseker M; Pfirrmann M; Kalmanti L; Rinaldetti S; Kohlbrenner K; Haferlach C; Schlegelberger B; Fabarius A; Seifarth W; Spieß B; Wuchter P; Krause S; Kolb HJ; Neubauer A; Hossfeld DK; Nerl C; Gratwohl A; Baerlocher GM; Burchert A; Brümmendorf TH; Hasford J; Hochhaus A; Saußele S; Baccarani M;
Leukemia; 2020 Aug; 34(8):2074-2086. PubMed ID: 32382082
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
[TBL] [Abstract][Full Text] [Related]
19. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
20. Predictive and Prognostic Implications of Variant Philadelphia Translocations in CML: Experience From a Tertiary Oncology Center in Southern India.
Kanakasetty GB; Kuntejowdahalli L; Thanky AH; Dasappa L; Jacob LA; Mallekavu SB; Kumari P
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):52-59. PubMed ID: 27743980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
